Literature DB >> 11567774

Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device.

J C Aguiar1, R C Hedstrom, W O Rogers, Y Charoenvit, J B Sacci, D E Lanar, V F Majam, R R Stout, S L Hoffman.   

Abstract

We compared the needle free jet device device Biojector with syringe/needle as a method to administer a DNA vaccine encoding the Plasmodium falciparum circumsporozoite protein (PfCSP) in albino rabbits. A group of three rabbits was injected by the intramuscular (IM) route using a syringe/needle combination, a second group IM with the Biojector device and a third group both IM and intradermal (ID) using the Biojector. When animals were immunized with the Biojector IM or IM/ID as compared to the syringe/needle IM, we observed 10- and 50-fold greater antibody titers, as measured by enzyme immunoassay (EIA) and indirect fluorescence antibody test (IFAT), respectively. We also observed that the Biojector conferred a greater ability to prime the immune system as compared with the needle. The subsequent boosting of all animals with a recombinant canary pox virus (ALVAC) expressing PfCSP induced significantly higher titers in both Biojector groups of rabbits as compared with the needle and naive animals. These results provided the foundation for a clinical trial using the same regime.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11567774     DOI: 10.1016/s0264-410x(01)00273-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

Review 1.  Effect of vaccine administration modality on immunogenicity and efficacy.

Authors:  Lu Zhang; Wei Wang; Shixia Wang
Journal:  Expert Rev Vaccines       Date:  2015-08-27       Impact factor: 5.217

Review 2.  Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

Authors:  Kimberly A Schoenly; David B Weiner
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

Review 3.  DNA vaccines for HIV: challenges and opportunities.

Authors:  David A Hokey; David B Weiner
Journal:  Springer Semin Immunopathol       Date:  2006-10-10

Review 4.  Genetic vaccination approaches against malaria based on the circumsporozoite protein.

Authors:  Sandra Scheiblhofer; Richard Weiss; Josef Thalhamer
Journal:  Wien Klin Wochenschr       Date:  2006       Impact factor: 1.704

5.  High-throughput generation of P. falciparum functional molecules by recombinational cloning.

Authors:  João Carlos Aguiar; Joshua LaBaer; Peter L Blair; Victoria Y Shamailova; Malvika Koundinya; Joshua A Russell; Fengying Huang; Wenhong Mar; Robert M Anthony; Adam Witney; Sonia R Caruana; Leonardo Brizuela; John B Sacci; Stephen L Hoffman; Daniel J Carucci
Journal:  Genome Res       Date:  2004-10       Impact factor: 9.043

Review 6.  Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).

Authors:  Michael Vaine; Shan Lu; Shixia Wang
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

7.  The genome of canarypox virus.

Authors:  E R Tulman; C L Afonso; Z Lu; L Zsak; G F Kutish; D L Rock
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

8.  DNA immunization with the cysteine-rich interdomain region 1 of the Plasmodium falciparum variant antigen elicits limited cross-reactive antibody responses.

Authors:  Dror I Baruch; Benoit Gamain; Louis H Miller
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

9.  Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.

Authors:  Jukka Hartikka; Vesselina Bozoukova; Jane Morrow; Denis Rusalov; Mark Shlapobersky; Qun Wei; Sou Boutsaboualoy; Ming Ye; Mary K Wloch; John Doukas; Sean Sullivan; Alain Rolland; Larry R Smith
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

10.  Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy.

Authors:  Magaly Chinchilla; Marcela F Pasetti; Sandra Medina-Moreno; Jin Yuan Wang; Oscar G Gomez-Duarte; Rick Stout; Myron M Levine; James E Galen
Journal:  Infect Immun       Date:  2007-05-14       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.